Telix Pharmaceuticals LtdTLX
Price (close)
$11.31
Market cap
$3.8B
P/E
—
Revenue (FY)
$803.8M
Net income
-$7.1M
Dividend yield
—
1-year total return
11.9%
Net margin
-0.9%
Revenue growth
55.6%
Debt / equity
0.94x
What Telix Pharmaceuticals Ltd does.
As an established leader and innovator in this field, Telix is differentiated by our deep expertise in radiopharmaceutical
to deliver patient outcomes globally. In order to achieve our mission and deliver on our strategy, Telix has structured the
strategies and prospects for future years , can be found in "Item 5. Operating and financial review and prospects" of this
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | $333.0M | $516.6M | $803.8M |
| Net income | — | $4.2M | $33.7M | -$7.1M |
| Free cash flow | — | $8.0M | $18.4M | -$43.0M |
More on TLX.
- Telix Pharmaceuticals Ltd summary
- Telix Pharmaceuticals Ltd financial statements
- Telix Pharmaceuticals Ltd key metrics
- Telix Pharmaceuticals Ltd health scores and style box
- Telix Pharmaceuticals Ltd earnings
- Telix Pharmaceuticals Ltd dividends
- Telix Pharmaceuticals Ltd valuation
- Telix Pharmaceuticals Ltd ownership and insiders
- Telix Pharmaceuticals Ltd peers
Figures from Telix Pharmaceuticals Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.